Company intelligence / Profile preview
Flow Pharma
Cleveland, Ohio, United Statesflowpharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Flow Pharma develops AI-guided T-cell immunotherapies targeting both viral diseases and cancers. Its lead program FLOVID‑20 showed protective efficacy in macaque monkeys against COVID‑19 in preclinical studies. Other programs include immunotherapies for Ebola/Marburg viruses and triple-negative breast cancer with promising animal data.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Therapeutic peptides (T-cell stimulating peptides)Immunotherapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
United States Department of Defense vaccine contractor for infectious disease vaccines
Beyond the preview
Go deeper on Flow Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flow Pharma.